24/7 Wall Street
05 Aug 2026, 13:50 UTC · 1h ago
GLP-1's Drove Eli Lilly's Record-Breaking Q2, but AI Will Be Its Future
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
05 Aug 2026, 13:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Eli Lilly raised its full-year revenue guidance to a range of $85 billion to $87 billion, up from the previous $82 billion to $85 billion range. — Upward guidance revisions for a large-cap company typically trigger immediate positive price action and signal strong demand.
+0.80Eli Lilly's Q2 revenue grew 48% year-over-year to $23 billion, significantly exceeding the Wall Street estimate of $20.7 billion. — Strong earnings beats and high growth rates validate the company's current commercial momentum.
+0.70Mounjaro has become the world's best-selling drug with $9.9 billion in quarterly sales, widening the gap over Novo Nordisk's GLP-1 offerings. — Dominance in the high-growth obesity market suggests a significant competitive advantage and market share gain.
+0.60Continue reading
6 related stories
Top 2 movers · tap to explore
Eli Lilly and Nvidia are investing up to $1 billion over five years in a joint AI lab for drug discovery and manufacturing. — While promising for long-term R&D efficiency, the impact is less immediate than quarterly financial beats.
+0.40Which stocks this story touches
Reported surging revenue, blockbuster drug sales, and a strong AI strategy leading to raised full-year guidance.
Collaborating with Eli Lilly on a joint AI lab and providing the technology for their AI supercomputer.
Mentioned as a rival with significantly lower quarterly sales for comparable GLP-1 drugs compared to Eli Lilly.
[mutual] Both companies compete directly in the GLP-1 weight-loss and diabetes drug market.
[a_to_b] Eli Lilly's AI supercomputer is built with Nvidia technology.
[mutual] The companies have a joint AI innovation lab with a commitment of up to $1 billion over five years.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
9m ago
